Search for content, post, videos

Novo Nordisk announces Phase 2 results

Novo Nordisk CMC Development
Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared with
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.